Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being ...

About one in five people with lymphoma have follicular lymphoma ... Primary mediastinal large B-cell lymphoma This is a rare type of DLBCL. Unlike regular large B-cell lymphoma, this type mainly ...

Follicular lymphoma is a diverse disease ... Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing ...

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

Kymriah was cleared by the FDA for the follicular lymphoma use last year as well, a little after Yescarta, adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute ...

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

In the U.S., BREYANZI is approved for treating relapsed or refractory large B-cell lymphoma (LBCL ... for adults with relapsed or refractory follicular lymphoma who have undergone at least ...